Filtered By:
Source: Journal of the American Society of Nephrology : JASN
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 16 results found since Jan 2013.
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform
Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in patients with CKD, including those receiving dialysis, although clinical trials have identified risks associated with ESA use. We evaluated the effects of changes in dialysis payment policies and product labeling instituted in 2011 on mortality and major cardiovascular events across the United States dialysis population in an open cohort study of patients on dialysis from January 1, 2005, through December 31, 2012, with Medicare as primary payer. We compared observed rates of death and major cardiovascular events in 2011 and 2012 with expected ra...
Source: Journal of the American Society of Nephrology : JASN - September 29, 2016 Category: Urology & Nephrology Authors: Chertow, G. M., Liu, J., Monda, K. L., Gilbertson, D. T., Brookhart, M. A., Beaubrun, A. C., Winkelmayer, W. C., Pollock, A., Herzog, C. A., Ashfaq, A., Sturmer, T., Rothman, K. J., Bradbury, B. D., Collins, A. J. Tags: Clinical Epidemiology Source Type: research
Contrasting Cholesterol Management Guidelines for Adults with CKD
In conclusion, these guidelines show high concordance for statin treatment for adults with CKD.
Source: Journal of the American Society of Nephrology : JASN - April 30, 2015 Category: Urology & Nephrology Authors: Colantonio, L. D., Baber, U., Banach, M., Tanner, R. M., Warnock, D. G., Gutierrez, O. M., Safford, M. M., Wanner, C., Howard, G., Muntner, P. Tags: Clinical Epidemiology Source Type: research
AKI and Long-Term Risk for Cardiovascular Events and Mortality
In conclusion, AKI associates with an elevated risk of cardiovascular mortality and major cardiovascular events, particularly heart failure and acute myocardial infarction.
Source: Journal of the American Society of Nephrology : JASN - December 29, 2016 Category: Urology & Nephrology Authors: Odutayo, A., Wong, C. X., Farkouh, M., Altman, D. G., Hopewell, S., Emdin, C. A., Hunn, B. H. Tags: Meta-Analysis Source Type: research
New Insights on the Risk for Cardiovascular Disease in African Americans: The Role of Added Sugars
African Americans are at increased risk for cardiovascular and metabolic diseases, including obesity, high BP, diabetes, CKD, myocardial infarction, and stroke. Here we summarize the current risks and provide an overview of the underlying risk factors that may account for these associations. By reviewing the relationship between cardiovascular and renal diseases and the African-American population during the early 20th century, the historic and recent associations of African heritage with cardiovascular disease, and modern population genetics, it is possible to assemble strong hypotheses for the primary underlying mechanis...
Source: Journal of the American Society of Nephrology : JASN - January 30, 2015 Category: Urology & Nephrology Authors: Saab, K. R., Kendrick, J., Yracheta, J. M., Lanaspa, M. A., Pollard, M., Johnson, R. J. Tags: Brief Reviews Source Type: research
Subclinical Atherosclerosis Measures for Cardiovascular Prediction in CKD
In conclusion, each measure improved cardiovascular risk prediction in subjects with CKD, with the greatest improvement observed with coronary artery calcium score.
Source: Journal of the American Society of Nephrology : JASN - January 30, 2015 Category: Urology & Nephrology Authors: Matsushita, K., Sang, Y., Ballew, S. H., Shlipak, M., Katz, R., Rosas, S. E., Peralta, C. A., Woodward, M., Kramer, H. J., Jacobs, D. R., Sarnak, M. J., Coresh, J. Tags: Clinical Epidemiology Source Type: research
HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients
High concentrations of HDL cholesterol are considered to indicate efficient reverse cholesterol transport and to protect from atherosclerosis. However, HDL has been suggested to be dysfunctional in ESRD. Hence, our main objective was to investigate the effect of HDL cholesterol on outcomes in maintenance hemodialysis patients with diabetes. Moreover, we investigated the associations between the major protein components of HDL (apoA1, apoA2, and apoC3) and end points. We performed an exploratory, post hoc analysis with 1255 participants (677 men and 578 women) of the German Diabetes Dialysis study. The mean age was 66.3 yea...
Source: Journal of the American Society of Nephrology : JASN - January 30, 2015 Category: Urology & Nephrology Authors: Silbernagel, G., Genser, B., Drechsler, C., Scharnagl, H., Grammer, T. B., Stojakovic, T., Krane, V., Ritz, E., Wanner, C., Marz, W. Tags: Clinical Research Source Type: research
N-Acetyl-{beta}-D-Glucosaminidase Does Not Enhance Prediction of Cardiovascular or All-Cause Mortality by Albuminuria in a Low-Risk Population
In conclusion, the nonsignificant improvement of risk prediction does not support the clinical use of NAG ratio in cardiovascular risk assessment in a low-risk group.
Source: Journal of the American Society of Nephrology : JASN - January 29, 2016 Category: Urology & Nephrology Authors: Solbu, M. D., Toft, I., Lochen, M.-L., Mathiesen, E. B., Eriksen, B. O., Melsom, T., Njolstad, I., Wilsgaard, T., Jenssen, T. G. Tags: Clinical Epidemiology Source Type: research
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up
In conclusion, after 2 years of observation, all groups showed a stable clinical disease course with respect to serious clinical events. However, patients under agalsidase-β dose-reduction and switch or a direct switch to agalsidase-α showed a decline of renal function independent of the eGFR formula used.
Source: Journal of the American Society of Nephrology : JASN - February 29, 2016 Category: Urology & Nephrology Authors: Lenders, M., Canaan-Kuhl, S., Kramer, J., Duning, T., Reiermann, S., Sommer, C., Stypmann, J., Blaschke, D., Uceyler, N., Hense, H.-W., Brand, S.-M., Wanner, C., Weidemann, F., Brand, E. Tags: Clinical Research Source Type: research
HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients
In conclusion, HDL cholesterol efflux capacity is not a prognostic cardiovascular risk marker in this cohort of patients with diabetes on hemodialysis.
Source: Journal of the American Society of Nephrology : JASN - February 27, 2017 Category: Urology & Nephrology Authors: Kopecky, C., Ebtehaj, S., Genser, B., Drechsler, C., Krane, V., Antlanger, M., Kovarik, J. J., Kaltenecker, C. C., Parvizi, M., Wanner, C., Weichhart, T., Säemann, M. D., Tietge, U. J. F. Tags: Brief Communications Source Type: research
Intradialytic Cardiac Magnetic Resonance Imaging to Assess Cardiovascular Responses in a Short-Term Trial of Hemodiafiltration and Hemodialysis
In conclusion, in this randomized, crossover study, there was no significant difference in the cardiovascular response to HDF or HD with cooled dialysate as assessed with intradialytic MRI.
Source: Journal of the American Society of Nephrology : JASN - March 31, 2017 Category: Urology & Nephrology Authors: Buchanan, C., Mohammed, A., Cox, E., Köhler, K., Canaud, B., Taal, M. W., Selby, N. M., Francis, S., McIntyre, C. W. Tags: Clinical Research Source Type: research
Sickle Cell Trait and the Risk of ESRD in Blacks
Blacks, compared with whites, have an increased risk of progression to end-stage renal disease (ESRD). Emerging evidence suggests that, in addition to APOL1 high-risk genotypes, hemoglobin variants, including sickle cell trait (SCT) and hemoglobin C trait, have a role in kidney disease in blacks. However, the association between these hemoglobin traits and ESRD remains unknown. In a large population-based cohort, the REasons for Geographic and Racial Differences in Stroke (REGARDS) study, we evaluated 9909 self-reported blacks (739 with SCT and 243 with hemoglobin C trait). Incident ESRD occurred in 40 of 739 (5.4%) indivi...
Source: Journal of the American Society of Nephrology : JASN - June 30, 2017 Category: Urology & Nephrology Authors: Naik, R. P., Irvin, M. R., Judd, S., Gutierrez, O. M., Zakai, N. A., Derebail, V. K., Peralta, C., Lewis, M. R., Zhi, D., Arnett, D., McClellan, W., Wilson, J. G., Reiner, A. P., Kopp, J. B., Winkler, C. A., Cushman, M. Tags: Clinical Epidemiology Source Type: research
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodialysis. Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). Significant accumulation of the drug was observed between days 1 and 8 with the 2.5-mg dose. The area under the concentration-time curve from 0 to 24 hou...
Source: Journal of the American Society of Nephrology : JASN - June 30, 2017 Category: Urology & Nephrology Authors: Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., Lipman, M. L. Tags: Clinical Research Source Type: research
Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function
Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo. However, whether combination therapy or statin alone resulted in cardiovascular benefit is uncertain. Therefore, we estimated GFR in 18,015 individuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in individuals with cardiovascular disease and creatinine clearance >30 ml/min) and examined post hoc the relationsh...
Source: Journal of the American Society of Nephrology : JASN - September 29, 2017 Category: Urology & Nephrology Authors: Stanifer, J. W., Charytan, D. M., White, J., Lokhnygina, Y., Cannon, C. P., Roe, M. T., Blazing, M. A. Tags: Clinical Research Source Type: research
Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia
Conclusions These results contrast with the detrimental effect of P inhibition observed in a murine model of C3 glomerulopathy and suggest that P contributes critically to aHUS pathogenesis. Inhibition of P in aHUS may be of therapeutic benefit.
Source: Journal of the American Society of Nephrology : JASN - June 29, 2018 Category: Urology & Nephrology Authors: Ueda, Y., Miwa, T., Gullipalli, D., Sato, S., Ito, D., Kim, H., Palmer, M., Song, W.-C. Tags: Basic Research Source Type: research
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis
Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any exposure–response relationship, suggest that the relationship between FGF-23 and cardiovascular disease risk may be noncausal.
Source: Journal of the American Society of Nephrology : JASN - June 29, 2018 Category: Urology & Nephrology Authors: Marthi, A., Donovan, K., Haynes, R., Wheeler, D. C., Baigent, C., Rooney, C. M., Landray, M. J., Moe, S. M., Yang, J., Holland, L., di Giuseppe, R., Bouma-de Krijger, A., Mihaylova, B., Herrington, W. G. Tags: Meta-Analysis Source Type: research
